Author(s): Gilham DE, Debets R, Pule M, Hawkins RE, Abken H
Abstract Share this page
Abstract Recent reports on the impressive efficacy of adoptively transferred T cells to challenge cancer in early phase clinical trials have significantly raised the profile of T cell therapy. Concomitantly, general expectations are also raised by these reports, with the natural aspiration to deliver this therapy over a wide range of tumor indications. Chimeric antigen receptors (CARs) endow T cell populations with defined antigen specificities that function independently of the natural T cell receptor and permit targeting of T cells towards virtually any tumor. Here, we review the current clinical application of CAR-T cells and relate clinical efficacy and safety of CAR-T cell trials to parameters considered critical for CAR engineering, classified as the three T's of CAR-T cell manipulation. Copyright © 2012 Elsevier Ltd. All rights reserved.
This article was published in Trends Mol Med
and referenced in Journal of Clinical & Cellular Immunology